Zevra Therapeutics earnings were $78.0M for the trailing 12 months ending Sep 30, 2026, with 164.6% growth year over year. The latest ZVRA earnings report on Sep 30, 2026 announced Q3 2026 earnings of $19.2M, up 119.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ZVRA reported annual earnings of $83.2M, with -178.9% growth.
ZVRA past earnings growth
How has ZVRA's earnings growth performed historically?
What were Zevra Therapeutics's earnings last quarter?
On ZVRA's earnings call on Nov 3, 2026, Zevra Therapeutics (NASDAQ: ZVRA) reported Q3 2026 earnings per share (EPS) of $0.31, up 3,200% year over year. Total ZVRA earnings for the quarter were $19.21 million. In the same quarter last year, Zevra Therapeutics's earnings per share (EPS) was -$0.01.
As of the last Zevra Therapeutics earnings report, Zevra Therapeutics is currently profitable. Zevra Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $78.02 million, a 120.85% increase year over year.
What was ZVRA's earnings growth in the past year?
As of Zevra Therapeutics's earnings date in Nov 3, 2026, Zevra Therapeutics's earnings has grown 164.58% year over year. This is 90 percentage points higher than the US Biotechnology industry earnings growth rate of 74.58%. ZVRA earnings in the past year totalled $78.02 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.